Literature DB >> 12973852

Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract.

Silvia Pizzi1, Cinzia Azzoni, Daniela Bassi, Lorena Bottarelli, Massimo Milione, Cesare Bordi.   

Abstract

BACKGROUND: The molecular pathogenesis of poorly differentiated endocrine carcinomas of the gastrointestinal tract (GI PDECs) remains unclear. It has been suggested that these lesions either originate from multipotent stem cells that also can serve as the origin of nonendocrine adenocarcinomas or arise due to the dedifferentiation of well-differentiated endocrine carcinomas (WDECs).
METHODS: Ten gastric and 9 colorectal PDECs, 9 gastric WDECs, and 12 colorectal carcinomas (CRCs) were analyzed for loss of heterozygosity (LOH) at 11q13 (MEN1), 17p13.1 (p53), 3p14.2 (FHIT), 3p21.3 (RASSF1A), and 18q23 (DCC/DPC4/Smad2), and for immunohistochemical expression of p53, FHIT, Rb, and p16.
RESULTS: PDECs exhibited high fractional allelic loss (FAL; 0.49), with frequent (> 40%) alterations in p53, Rb, MEN1, FHIT, and 18q. No significant differences were found between gastric and colorectal PDECs. Gastric WDECs also exhibited high FAL (0.44), with frequent alterations in Rb and/or p16, MEN1, and 3p21. CRCs exhibited a low level of FAL (0.23), with frequent (> 50%) p16 and p53 alterations. When gastric PDECs and WDECs were compared, substantial similarities were found with respect to FAL (0.42 vs. 0.44) and with respect to individual gene alterations, except in p53, which was consistently altered only in PDECs. CRCs, which were characterized by a lower FAL (0.56 vs. 0.23) and which lacked alterations in both 3p and Rb, were found to be significantly different from colorectal PDECs.
CONCLUSIONS: GI PDECs demonstrated a high level of chromosomal instability; consistent inactivation of both the p53 and p16/Rb pathways; and frequent LOH at 3p (possibly involving FHIT), the MEN1 locus, and 18q. The profile of genetic alterations in PDECs was more consistent with the profile in WDECs than with the profile in CRCs. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11621

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973852     DOI: 10.1002/cncr.11621

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

2.  Smad4 induces cell death in HO-8910 and SKOV3 ovarian carcinoma cell lines via PI3K-mTOR involvement.

Authors:  Yushuang Yao; Zhe Zhang; Fanmao Kong; Zhuqing Mao; Zhaoyuan Niu; Chuan Li; Aiping Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-10

3.  The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.

Authors:  L van der Weyden; K K Tachibana; M A Gonzalez; D J Adams; B L Ng; R Petty; A R Venkitaraman; M J Arends; A Bradley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 4.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

5.  Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Silvia Pizzi; Tiziana D'Adda; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2005-10-22       Impact factor: 4.064

6.  Effect of deleted pancreatic cancer locus 4 gene transfection on biological behaviors of human colorectal carcinoma cells.

Authors:  De-Sheng Xiao; Ji-Fang Wen; Jing-He Li; Zhong-Liang Hu; Hui Zheng; Chun-Yan Fu
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 7.  Criteria for malignancy in gastrointestinal endocrine tumors.

Authors:  Cesare Bordi; Tiziana D'Adda; Cinzia Azzoni; Silvia Pizzi; Lorena Bottarelli; Francesca Mormandi; Tommaso Antonetti; Tu Vinh Luong; Guido Rindi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 8.  Historical, current and future perspectives on gastrointestinal and pancreatic endocrine tumors.

Authors:  Susanne van Eeden; G Johan A Offerhaus
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

9.  Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.

Authors:  Hongling Zhao; Niloy J Iqbal; Vineeth Sukrithan; Cari Nicholas; Yingjiao Xue; Cindy Yu; Joseph Locker; Juntao Zou; Edward L Schwartz; Liang Zhu
Journal:  Cancer Res       Date:  2020-04-07       Impact factor: 12.701

10.  The retinoblastoma protein, RB, is required for gastrointestinal endocrine cells to exit the cell cycle, but not for hormone expression.

Authors:  Yang Wang; Subir K Ray; Philip W Hinds; Andrew B Leiter
Journal:  Dev Biol       Date:  2007-09-07       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.